EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma

Zeping Yang, Yuanqing Wu, Feizhi Kong, Yue Zhang, Lijun Jia, Chu Tang, Fu Wang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zeping Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an 71…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Histone Deacetylase 6, Histone Deacetylase Inhibitors. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Xi'an Municipal Bureau of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Basic Research Program of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylase 6 (HDAC6) is a pivotal epigenetic regulator and is involved in the tumorigenesis and progression. Our previous study revealed that HDAC6 is overactivated in hepatocellular carcinoma (HCC), and identified SelSA as a novel HDAC6 inhibitor (HDAC6i) for HCC therapy. In this work, we optimized this inhibitor and discovered 14a as a novel HDAC6i with better efficacy against HDAC6 and HepG2 cells than SelSA through structure-activity relationship (SAR) studies. The flow cytometry indicated that 14a markedly induced apoptosis and cell cycle arrest at the S phase in HepG2 cells. Mechanistic studies demonstrated that 14a effectively downregulated the levels of HDAC6 and the phosphorylation of ERK1/2, and attenuated the migration, invasion, and clonogenicity of HepG2 cells. More crucially, 14a possessed more potency to suppress tumor growth in HepG2 xenograft models compared to SelSA, without obvious toxicity. In summary, 14a represents a novel HDAC6i with anti-HCC effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHistone Deacetylase 6Histone Deacetylase InhibitorsAntineoplastic AgentsDrug DiscoveryHumansAnimalsStructure-Activity RelationshipHep G2 CellsApoptosisMiceCell ProliferationMice, Nude

Substanzen

Histone Deacetylase 6Histone Deacetylase InhibitorsHDAC6 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an 710126, Shaanxi, China.
  • Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi, China.
  • Institute of Medical Engineering, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.

ORCID-Profile: Fu Wang

Förderung

  • Xi'an Municipal Bureau of Science and Technology
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Natural Science Basic Research Program of Shaanxi Province
  • Xidian University
  • Guangzhou Municipal Science and Technology Project
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Wu, Y., Kong, F., Zhang, Y., Jia, L., Tang, C., & Wang, F. (2026). Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02763

Vancouver

Yang Z, Wu Y, Kong F, Zhang Y, Jia L, Tang C, et al. Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02763

BibTeX
@article{Yang2026,
  author = {Yang, Zeping and Wu, Yuanqing and Kong, Feizhi and Zhang, Yue and Jia, Lijun and Tang, Chu and Wang, Fu},
  title = {Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02763}
}
Kostenlos starten →